2-(4-benzyloxyphenyl)-2,5-dihydroxy-7-methoxy-4-chromanon | 78983-48-9

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 英文名称: 2-(4-benzyloxyphenyl)-2,5-dihydroxy-7-methoxy-4-chromanon
• 英文别名: 2-[4-(benzyloxy)phenyl]-2,5-dihydroxy-7-methoxy-3,4-dihydro-2H-1-benzopyran-4-one；2,5-dihydroxy-7-methoxy-2-(4-phenylmethoxyphenyl)-3H-chromen-4-one
• CAS: 78983-48-9
• 化学式: C₂₃H₂₀O₆
• 分子量: 392.408
• InChiKey: OUAZLWHOOTXVCE-UHFFFAOYSA-N

物化性质

• 沸点：
  645.5±55.0 °C(Predicted)
• 密度：
  1.350±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  85.2
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-(4-benzyloxyphenyl)-2,5-dihydroxy-7-methoxy-4-chromanon 在 palladium on activated charcoal 氢气 作用下， 以 乙醇 为溶剂， 反应 0.03h， 生成 4',5-二羟基-7-甲氧基黄酮
  参考文献：
  名称：

  Protogenkwanin, a new flavonoid from equisetum arvense L

  摘要：

  DOI：

  10.1016/s0040-4020(01)92024-1
• 作为产物：
  描述：

  4-苯甲氧基苯(甲)酰氯 在 吡啶 、 sodium hydroxide 、 水 作用下， 反应 25.0h， 生成 2-(4-benzyloxyphenyl)-2,5-dihydroxy-7-methoxy-4-chromanon
  参考文献：
  名称：

  Protogenkwanin, a new flavonoid from equisetum arvense L

  摘要：

  DOI：

  10.1016/s0040-4020(01)92024-1

文献信息

• Natural product derivatives for inhibiting cellular necroptosis, ferroptosis and oxytosis
  申请人：Institut National de la Sante et de la Recherche Medicale (INSERM)

  公开号：US11224586B2

  公开（公告）日：2022-01-18

  The present invention relates to a compound of the following general formula (I); or a pharmaceutically acceptable salt and/or solvate thereof, for use as drug, particularly intended for inhibiting a programmed cell death route selected from the group consisting of ferroptosis, oxytosis and cellular necroptosis. The present invention also relates to a compound of general formula (I) for use as a drug for neuroprotection as well as for preventing and/or treating disorders associated with cellular necroptosis or ferroptosis. The present invention also relates to a pharmaceutical composition comprising a compound of general formula (I), or a pharmaceutically acceptable salt and/or solvate thereof. The present invention also encompasses the use of a compound of the general formula (I) for organs preservation.

  本发明涉及以下通式(I)的化合物；或其药学上可接受的盐和/或溶液，可用作药物，特别是用于抑制选自铁变性、氧变性和细胞坏死的程序性细胞死亡途径。本发明还涉及一种通式（I）化合物，用于神经保护以及预防和/或治疗与细胞坏死或铁中毒相关的疾病。本发明还涉及一种药物组合物，其中包含通式（I）化合物或其药学上可接受的盐和/或溶液。本发明还包括通式（I）化合物在器官保存方面的用途。
• Natural Product Derivatives For Inhibiting Cellular Necroptosis, Ferroptosis And Oxytosis
  申请人：lnstitut National de Ia Sante et de Ia Recherche Medicale (INSERM)

  公开号：US20190262306A1

  公开（公告）日：2019-08-29

  The present invention relates to a compound of the following general formula (I); or a pharmaceutically acceptable salt and/or solvate thereof, for use as drug, particularly intended for inhibiting a programmed cell death route selected from the group consisting of ferroptosis, oxytosis and cellular necroptosis. The present invention also relates to a compound of general formula (I) for use as a drug for neuroprotection as well as for preventing and/or treating disorders associated with cellular necroptosis or ferroptosis. The present invention also relates to a pharmaceutical composition comprising a compound of general formula (I), or a pharmaceutically acceptable salt and/or solvate thereof. The present invention also encompasses the use of a compound of the general formula (I) for organs preservation.
• [EN] NATURAL PRODUCT DERIVATIVES FOR INHIBITING CELLULAR NECROPTOSIS, FERROPTOSIS AND OXYTOSIS<br/>[FR] DÉRIVÉS DE PRODUITS NATURELS POUR L'INHIBITION DE LA NÉCROPTOSE CELLULAIRE, DE LA FERROPTOSE ET DE L'OXYTOSIS
  申请人：INST NAT SANTE RECH MED

  公开号：WO2018073321A1

  公开（公告）日：2018-04-26

  The present invention relates to a compound of the following general formula (I); or a pharmaceutically acceptable salt and/or solvate thereof, for use as drug, particularly intended for inhibiting a programmed cell death route selected from the group consisting of ferroptosis, oxytosis and cellular necroptosis. The present invention also relates to a compound of general formula (I) for use as a drug for neuroprotection as well as for preventing and/or treating disorders associated with cellular necroptosis or ferroptosis. The present invention also relates to a pharmaceutical composition comprising a compound of general formula (I), or a pharmaceutically acceptable salt and/or solvate thereof. The present invention also encompasses the use of a compound of the general formula (I)for organs preservation.